Ropinirole Dosage Guide + Max Dose, Adjustments

Print

Save

Medically reviewed by Drugs.com. Last updated on Mar 17, 2023.

Applies to the following strengths: 12 mg; 6 mg; 2 mg; 4 mg; 8 mg; 0.25 mg; 0.5 mg; 1 mg; 5 mg; 3 mg; 0.25 mg-0.5 mg-1 mg

Usual Adult Dose for:

• Parkinson’s Disease
• Restless Legs Syndrome

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Parkinson’s Disease

Immediate-release tablets:
Initial: 0.25 mg orally three times daily

After 1 week, the dose may be titrated up in weekly increments based on individual efficacy and tolerability:
Week 2: give 0.5 mg orally 3 times daily
Week 3: give 0.75 mg orally 3 times daily
Week 4: give 1 mg orally 3 times daily
After week 4, increase by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, then increase by 3 mg/day on a weekly basis up to a maximum daily dose of 24 mg
Maximum Dose: 8 mg orally three times a day

Extended-release tablets:
Initial: 2 mg orally once daily for 1 to 2 weeks, followed by increases of 2 mg/day at 1-week or longer intervals, depending on therapeutic response and tolerability
Maximum dose: 24 mg orally once a day

Patients may switch from immediate-release to extended-release: The initial dose of extended-release tablet should most closely match the total daily dose of immediate-release formulation. Following conversion, adjust dose depending on response and tolerability.

Comments:

• If significant interruption in therapy occurs, retitration may be necessary; upon discontinuation, this drug should be gradually tapered over a 7-day period.
• The extended-release tablet is designed to release medication over a 24-hour period, if rapid gastrointestinal transit occurs, and tablet residue is observed in the stool, there is a risk of incomplete release of medication,

Use: For the treatment of Parkinson’s disease.

Usual Adult Dose for Restless Legs Syndrome

Immediate-release tablets:
Initial: 0.25 mg orally once a day on Day 1 and Day 2
Dose titration: May titrate as follows based on individual efficacy and tolerability:
Days 3 to 7: give 0.5 mg orally once a day

• Week 2: give 1 mg orally once a day
• Week 3: give 1.5 mg orally once a day
• Week 4: give 2 mg orally once a day
• Week 5: give 2. 5 mg orally once a day
• Week 6: give 3 mg orally once a day
• Week 7: give 4 mg orally once a day

Maximum Dose: 4 mg orally once a day

Comments:

• Take 1 to 3 hours before bedtime.
• In clinical trials, this drug was not tapered prior to discontinuation.

Use: For the treatment of moderate to severe Restless Legs Syndrome.

Renal Dose Adjustments

Parkinson’s disease:
Moderate renal impairment (CrCl 30 to 50 mL/mi): No dosage adjustment is necessary
Severe renal impairment without regular dialysis: No data available

Restless Leg Syndrome:
Moderate renal impairment (CrCl 30 to 50 mL/min): No dosage adjustment is necessary
Severe renal impairment without regular dialysis: No data available

Liver Dose Adjustments

Dose adjustments may be required; however, no specific guidelines have been suggested. Caution is recommended.

Dose Adjustments

Doses are individually titrated based on efficacy and tolerability.

Parkinson’s disease:

• If this drug is administered as adjunct therapy to levodopa, the concurrent dose of levodopa may be decreased gradually as tolerated; the average dose reduction of levodopa was 31% and 34% with immediate-release and extended-release tablets, respectively.

Drug interruption:

• If significant interruption in therapy occurs, this drug may need to be retitrated.

Drug discontinuation:

• Immediate-release tablets: Reduce the frequency of administration from 3 times a day to 2 times a day for 4 days, then once a day for 3 days, prior to discontinuation.
• Extended-release tablets: Gradually discontinue over a 7-day period

Precautions

Safety and efficacy of ropinirole have not been established in patients younger than 18 years.

Safety and efficacy of the extended-release product have not been established in patients with Restless Legs Syndrome (RLS).

Consult WARNINGS section for additional precautions.

Dialysis

Peritoneal dialysis: Data not available

End stage renal disease (ESRD) on hemodialysis:
Parkinson’s disease, Immediate-release:

• Initial dose: 0.25 mg orally 3 times a day
• Dose titration should be based on tolerability and need for efficacy
• Maximum dose: 6 mg orally 3 times a day

Parkinson’s disease, Extended-release:

• Initial dose: 2 mg orally once a day
• Dose titration should be based on tolerability and need for efficacy
• Maximum dose: 18 mg orally once a day

Restless Leg Syndrome:

• Initial dose: 0.25 mg orally once a day
• Dose titration should be based on tolerability and need for efficacy
• Maximum dose: 3 mg orally once a day

Comments: Supplemental doses after dialysis are not required.

Other Comments

Administration advice:

• May take with or without food
• If a dose is missed, take your next dose as scheduled; do not double your next dose
• Extended-release products should be taken once a day at a similar time each day; they should not be chewed, crushed, or split
• Restless Leg Syndrome: Take once a day 1 to 3 hours before bedtime

General:

• If significant interruption to therapy occurs, this drug should be retitrated.
• Parkinson’s Disease: This product should be tapered before discontinuation.
• Restless Legs Syndrome: This drug was not tapered to discontinuation during clinical trials.

Monitoring:

• Cardiovascular: Monitor for signs and symptoms of orthostatic hypotension, particularly during dose escalation; consider blood pressure monitoring at the start of treatment, especially in patients with significant cardiovascular disease.
• Nervous System: Monitor for somnolence and drowsiness
• Dermatologic: Monitor for melanomas; consider periodic skin examinations by dermatologists.
• Psychiatric: Question patients about new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges.

Patient advice:

• This drug frequently causes drowsiness; patients should not drive a car or operate machinery or other potentially dangerous activities until it is determined how this drug affects their mental and/or motor performance.
• Patients should be instructed to report episodes of sudden onset of sleep, new or worsening dyskinesia, new or worsening compulsive behaviors and/or unusual urges.
• Patients should be instructed to report changes in the size, shape, or color of moles on their skin and should have their skin checked on a regular basis for melanomas.
• Patients should be aware that this drug may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down.
• Patients should speak to their physician or health care provider if they become pregnant, intend to become pregnant, or are breastfeeding.

More about ropinirole

• Check interactions
• Compare alternatives
• Pricing & coupons
• Reviews (320)
• Drug images
• Side effects
• Patient tips
• During pregnancy
• Support group
• Drug class: dopaminergic antiparkinsonism agents
• Breastfeeding
• En español

Patient resources

• Drug Information
• Ropinirole Extended-Release Tablets
• Ropinirole Tablets

Other brands

Requip, Requip XL

Professional resources

• Prescribing Information

Related treatment guides

• Restless Legs Syndrome
• Parkinson’s Disease
• Periodic Limb Movement Disorder
• Tardive Dyskinesia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Side Effects, Dosage, Uses, and More

Ropinirole is a prescription medication used for the treatment of movement disorders. It works by mimicking dopamine in your brain.

This medication is taken orally and is available in both immediate-release and extended-release tablets. Extended-release medications are released into your bloodstream more slowly throughout the day, while immediate-release medications take effect more quickly.

Ropinirole was previously sold under the brand names Requip and Requip XL. Both brand names have since been discontinued due to business reasons, rather than safety. Ropinirole is still available in generic formulas.

Depending on your treatment plan, this medication may be used as part of combination therapy. This means you would take ropinirole with other medications, as directed by a doctor.

Read on to learn more about ropinirole, including its uses and potential benefits, as well as the possible risks and side effects you should discuss with a doctor.

Taking ropinirole may cause side effects. Clinical trials showed side effects ranging from mild to severe associated with ropinirole.

It’s important to discuss possible side effects with a doctor before taking this medication. If you experience side effects after taking this medication, let the prescribing doctor or a member of your care team know.

Common side effects

The most common side effects associated with ropinirole include:

• significant drowsiness and sleepiness
• involuntary movements in your face and body known as dyskinesia
• nausea
• dizziness
• confusion
• trouble concentrating
• hallucinations or seeing or hearing things that are not real
• temporary memory loss
• headache
• flushing or warm, red skin
• dry mouth
• sweating
• chest pain
• edema, or swelling
• back pain
• high blood pressure
• low blood pressure, which can cause fainting
• indigestion, which can cause bloating, heartburn, and gas
• heart palpitations
• edema or swelling in the legs
• insomnia
• increased infections
• vision problems such as blurry vision or double vision

Mild side effects may go away on their own. But if they’re more severe or don’t go away, talk with a doctor or pharmacist. Some side effects, such as sleep disorders and indigestion, may still be experienced during the maintenance phase of taking the medication.

Severe side effects

While sudden drowsiness or sleepiness isn’t always harmful on its own, it can become dangerous if you’re in the middle of activities or operating heavy machinery when it occurs. This could increase your risk for falls or accidents. Some people taking ropinirole experienced severe somnolence after 1 year of taking this medication.

Additionally, there are other potentially severe or life threatening side effects that can warrant a call to 911 or your local emergency services right away. Those side effects and their symptoms may include the following:

• fainting or loss of consciousness
• heart rate changes, especially if you have a history of heart disease
• low blood pressure that leads to falls
• high fever
• muscle tightness

Other severe side effects may be psychiatric in nature. You should communicate with the doctor who prescribed your medication if you experience symptoms such as:

• hallucinations
• paranoia, or increased suspicion and distrust of people
• significant confusion
• aggressive behavior
• increasing agitation
• intense urges, such as those related to gambling, shopping, binge-eating, or sex

Ropinirole can also bind to melanin in the skin, according to animal studies. This may possibly increase the risk of melanoma, a serious skin cancer. See your doctor if you notice any rapid changes in size, shape, and color of any moles on your skin.

Be sure to follow the doctor’s instructions for taking ropinirole and any other medications. Your dosage may vary.

Uses

Ropinirole belongs to a class of drugs called dopamine agonists. These have the same effect in your central nervous system as the natural chemical dopamine. Ropinirole is primarily used in the treatment of movement disorders, including Parkinson’s disease and restless legs syndrome.

The body needs dopamine to help control movement. In diseases such as Parkinson’s, the cells that produce dopamine die. Ropinirole works by acting in place of the missing dopamine without having to be converted.

Before use

The exact dosage and dosing instructions for ropinirole may depend on the following factors:

• the condition being treated
• how severe the condition is
• your age
• other medical conditions

Tell your doctor about any side effects you experience after the initial dose and whether you have experienced any adverse effects from other medications you’ve taken.

Dosage

Ropinirole is taken daily by mouth. To work effectively, the medication must be swallowed whole — do not crush or divide the tablets.

You can take ropinirole with or without food. However, taking it with food may help prevent an upset stomach.

If you need to stop taking this drug, a doctor will slowly reduce your dosage, usually over the course of 7 days. Do not stop taking ropinirole suddenly, and do not change your dosage without talking with a doctor.

The prescribing doctor will provide specific dosing information related to your condition. Below are the general guidelines for this medication.

Parkinson’s disease

For Parkinson’s disease treatment, a doctor may prescribe ropinirole in 2-milligram (mg) doses daily for 1 to 2 weeks. Depending on medication response and side effects, the dose may be increased every week in 2-mg intervals per day.

The doctor may also initially prescribe immediate-release tablets. They may switch you to extended-release tablets as you respond to the medication. The maximum dose per day (daily) is 24 mg.

Restless legs syndrome

If taking ropinirole for restless legs syndrome, your doctor will start you on a daily dose of 0.25 mg. For best results, take the medication 1 to 3 hours before bedtime.

Depending on your response to the medication, your doctor may gradually increase your dose according to the following intervals:

• Days 3 to 7: 0. 5 mg per day
• Week 2: 1 mg per day
• Week 3: 1.5 mg per day
• Week 4: 2 mg per day
• Week 5: 2.5 mg per day
• Week 6: 3 mg per day
• Week 7: 4 mg per day

In renal disease

Ropinirole may be initially prescribed in doses of 2 mg daily if you have renal impairment. If you receive dialysis, the maximum dose per day (daily) is 18 mg.

How to handle a missed dose

It’s important to take ropinirole daily, as prescribed by your doctor. If you miss a dose, the medication may not work as well, or it may stop working completely. For this drug to work well, a certain amount needs to be in your body at all times.

If you do miss a dose, take ropinirole as soon as you remember. However, if you remember just a few hours before your next scheduled dose, take only one dose. Never try to catch up by taking two doses at once. This could result in dangerous side effects.

Storage and disposal

Keep ropinirole at room temperature, between 68 and 77°F (20 and 25°C). You should also keep this medication away from moisture and light. Be sure to store the tablets in their container and seal the lid tightly after each use.

If you need to dispose of unwanted or unused ropinirole tablets, ask a doctor or pharmacist, or search for local medication take-back programs. Never throw away your medications in the trash or flush them down a toilet.

Taking ropinirole may cause some unintended effects, such as allergic reactions.

Allergy warning

Ropinirole can cause a severe allergic reaction, which may cause symptoms such as:

• trouble breathing
• trouble swallowing
• swelling of your tongue, lips, face, or throat
• rash
• hives

If you develop these symptoms, call 911 or your local emergency services, or go to the nearest emergency room.

It’s also important to avoid taking ropinirole if you’ve had a previous allergic reaction to it.

Pregnancy and breastfeeding

Talk with the doctor if you’re pregnant or planning to become pregnant. Ropinirole should be used only if the potential benefit justifies the potential risk.

Animal studies of the drug have suggested that when used during pregnancy, it may cause birth defects or miscarriage. However, more studies are needed.

While there haven’t been any studies to show whether ropinirole can harm babies via breast milk, the medication may decrease lactation.

For children and older adults

It has not been confirmed that ropinirole is safe and effective for use in children younger than 18 years.

Dose adjustments may not be needed in adults 65 years and older since the dose needs to be adjusted for each person’s response. That said, older adults can process drugs more slowly so a higher amount of a drug stays in the body for a longer time, which could increase the risk of side effects.

Ropinirole may interact with the following drugs:

• Cytochrome P450 1A2 (CYP1A2) inhibitors and inducers, which are found in several types of medications, such as fluvoxamine for mental health conditions, and certain drugs taken for GI disorders, sleep disorders, and bacterial infections
• estrogens, including those in birth control pills
• other dopamine antagonists

Before using ropinirole, talk with a doctor about any other prescription drugs, supplements, and herbs you’re currently taking. This will help reduce the risk of a possible drug interaction.

Symptoms of ropinirole overdose may include:

• dizziness
• nausea or vomiting
• coughing
• excessive sweating
• heart palpitations
• extreme fatigue
• somnolence
• confusion
• agitation

If you think you’ve taken too much ropinirole, call your doctor or local poison control center. If your symptoms are severe, call your local emergency services or go to the emergency room right away.

While ropinirole may help replace missing dopamine in the treatment of movement disorders, this isn’t the only option available. Talk with a doctor about all of the treatment options for your condition. You may also find that one drug works better than others.

Other types of dopamine agonists may include:

• apomorphine hydrochloride (Kynmobi)
• apomorphine hydrochloride injections (Apokyn)
• pramipexole (Mirapex, Mirapex ER)
• rotigotine transdermal (Neupro)

Ropinirole is a prescription medication that may help treat movement disorders. It’s a dopamine agonist that’s approved for the treatment of Parkinson’s disease and restless legs syndrome. However, this medication is not approved for pediatric patients.

Sudden drowsiness or sleepiness is one of the most common side effects associated with this medication. It’s important to discuss possible side effects with a doctor before use, especially if you take other medications or have an underlying health condition.

effective methods and rules of application

An article about the treatment of Parkinson’s disease with pills and how to use them correctly. Find out what pills exist and how to choose the most effective ones for Parkinson’s disease.

Parkinson’s disease is a progressive disease of the nervous system, which is manifested by impaired movement and difficulty in maintaining balance. Already today this disease is diagnosed in millions of people in the world, and every year the number of cases is only increasing. Currently, the only way to manage the disease and reduce its manifestations is the treatment with drugs that improve the patient’s quality of life and delay its progression.

Typically, specially formulated drugs in tablet form are used to treat Parkinson’s disease. The effectiveness of the course of treatment directly depends on the correctness of their use. Before you start taking medicines, you must carefully study the instructions for use and consult a professional doctor.

In this article, we will talk about how the pills help to cope with Parkinson’s disease, as well as give recommendations on the correct use of drugs, reduce the risks of possible side effects and what nuances of taking medicines should be taken into account and what indicators should be monitored during the course of treatment.

Parkinson’s disease: treatment with pills and their use

What is Parkinson’s disease

Parkinson’s disease is a neurodegenerative disease that manifests itself in the form of impaired movement and coordination. It occurs due to a decrease in the amount of dopamine in the brain, which is responsible for transmitting signals between neurons.

Positive

0%

Negative

0%

Neutral

0%

Tablet treatment

Tablets are the main treatment for Parkinson’s disease. They can stop or slow the progression of the disease and improve the quality of life of patients.

The drugs are divided into two groups: levodopa and non-levodopa. Levodopa is a dopamine precursor that is converted into it in the brain. Nelevodopa are other drugs that can increase dopamine levels or mimic its effects.

How to use tablets

Drugs are selected individually, depending on the severity of the symptoms and the tolerance of the patient. Non-levodopa drugs are usually prescribed first, followed by levodopa. At the initial stages of the disease, the use of monotherapy is acceptable.

When using tablets, the exact dosage must be observed and possible side effects such as nausea, dizziness, hypotension and dyskinesia should be monitored. It is also important to consider the incompatibility of tablets with certain other drugs, including tranquilizers and antidepressants.

Conclusion

The treatment of Parkinson’s disease with pills is an important and effective method of dealing with the disease. However, this method requires careful selection of drugs and compliance with the individual dosage for each patient.

What is Parkinson’s disease?

Parkinson’s disease is a chronic disease of the central nervous system that results in movement, coordination and balance disorders. It is one of the most common neurological diseases and most often manifests itself in older people.

In Parkinson’s disease, there is a loss of neurons responsible for the production of dopamine, a substance that helps control movement and coordination. This leads to the three main symptoms of the disease: trembling, congestion, and decreased muscle strength. In addition, patients may experience fatigue, muscle and joint pain, sleep problems, and digestive disturbances.

Parkinson’s disease is incurable, but drug therapy can improve patients’ quality of life and slow the progression of symptoms.

Parkinson’s Tablets

Parkinson’s disease is a neurodegenerative disorder that causes movement problems, tremors, loss of balance and coordination, and physical and mental fatigue. Various types of pills are used to treat this disease, which help reduce symptoms and slow the progression of the disease.

Levodopa

Levodopa is one of the most common medicines used to treat Parkinson’s disease. It increases the level of dopamine in the brain, which helps reduce the symptoms of the disease. Levodopa is often used in combination with other medicines, such as carbidopa, which help maintain blood levels of levodopa.

Anticholinergics

Anticholinergics block acetylcholine receptors in the brain, which may help reduce trembling and muscle stiffness in patients with Parkinson’s disease. These tablets may cause side effects such as dry mouth and difficulty urinating.

Dopamine agonists

Dopamine agonists mimic the action of dopamine in the brain to help improve coordination, balance and movement in patients with Parkinson’s disease. Some of these tablets may cause drowsiness, dizziness, and low blood pressure.

Exemplary names of tablets for the treatment of Parkinson’s disease Type of tablets Exemplary names0076

Anticholinergics Artane, Cogentin, Kemadrin Dopamine agonists Mirapex, Requip, Neupro, Apokyn

Benefits of treating Parkinson’s tablets

Parkinsonism is a complex disease that requires long-term treatment. Treating Parkinson’s with pills has many benefits.

• Fast acting: Tablets act quickly and patients notice improvement within a few days.
• Relief of symptoms: Tablets can effectively reduce shaking, slow down movements and reduce muscle tightness. They make the daily life of patients more comfortable and maintain their quality of life.
• Ease of use: Tablets are easy to take and do not require special storage conditions.
• Safety: Tablet treatment is safe and easy to use.

Depending on the severity of the symptoms and the individual patient, the doctor may prescribe different types of pills to treat parkinson’s. Patients should follow the doctor’s recommendations and not exceed the dosage of medications.

Parkinson’s treatment with pills is regarded as one of the most convenient ways to reduce symptoms and improve the quality of life of patients.

How to take the pills for Parkinson’s disease?

Parkinson’s disease is a chronic disease that progresses over time and requires ongoing medical treatment. The main drug to combat this disease is levodopa. But how to take pills for Parkinson’s disease?

It is important to take regularly. Tablets should be taken strictly at the appointed time and do not skip doses, even if the symptoms of the disease do not appear at the moment. Violation of the regimen can lead to an increase in the amount of the drug in the blood, cause side effects, or vice versa, reduce the effectiveness of treatment.

The correct dosage of must be observed. The dose of tablets should be prescribed by the attending physician, taking into account the severity of the disease, the age and weight of the patient. Often a combination of drugs is used to effectively control Parkinson’s symptoms, so you should not change the dosage yourself or stop taking any drug without consulting your doctor.

It is important to keep the interval between taking tablets. If the doctor has prescribed taking the pills at a certain time, it is necessary to observe equal intervals between doses. This regulates the amount of drug in the blood and allows you to achieve a stable level of therapeutic substance in the body.

Tell your doctor about side effects of . If you experience any side effects such as nausea, vomiting, dizziness, drowsiness while taking the medicine, you should contact your doctor. The doctor may adjust the dosage or prescribe a different drug to eliminate unwanted effects.

Side effects of Parkinson’s pills

Parkinson’s pills can be effective in managing the symptoms of the disease, but they can also have some side effects.

One of the most common side effects of these tablets is nausea. Some people may also experience vomiting, which can impair the absorption of drugs and lead to a decrease in the effectiveness of treatment.

Another potential side effect of Parkinson’s pills is difficulty urinating or worsening urinary problems. This can happen due to an increase in the flow of urine into the bladder, causing it to expand and have less control over the exit of urine from the body.

Some patients may experience allergic reactions to Parkinson’s tablets. This can be expressed in the form of a skin rash, itching or swelling. If you have an allergic reaction to the tablets, you should contact your doctor so they can prescribe a different drug.

Some Parkinson’s tablets may cause drowsiness or dizziness, which may impair working ability or increase the risk of falling. In such cases, it is best to refrain from driving or performing other cognitively limiting tasks.

Finally, in some cases, the use of Parkinson’s pills may cause problems with consciousness, such as hallucinations or disorientation. If you notice these symptoms, contact your doctor for corrective treatment.

How long should I take my Parkinson’s tablets?

The duration of taking the Parkinson’s tablets depends on the individual characteristics of each patient. The decision about when to stop taking medications should be made by your doctor.

At the initial manifestations of Parkinson’s disease, treatment may be short-term. Some patients develop symptoms suddenly and are given a course of therapy, which is then stopped. However, if the disease becomes chronic, tablets become a necessary part of the routine treatment.

If medications have been prescribed to control symptoms, continue as long as the effect of the medications persists. It is also important to understand that taking the pills should not be interrupted without the consent of the doctor, as this may lead to a deterioration in the patient’s condition.

In general, taking pills for Parkinson’s disease is a long-term process that requires regular monitoring by the doctor to adjust the dosage and take other medications if necessary.

Drugs for the treatment of Parkinson’s disease in Russia

Parkinson’s disease is a neurodegenerative disease characterized by impaired motor functions and can also lead to mental disorders. In Russia, various drugs are used to treat this disease, which are prescribed by a doctor based on the severity of the symptoms and the patient’s condition.

1. Levodopa is the most effective and widely used drug for the treatment of Parkinson’s disease in Russia. It contains levodopa, a precursor to dopamine, which helps replenish the deficiency of this neurotransmitter in the brain. The drug can be used as monotherapy or combined with other drugs.
2. Dopaminergic agonists are drugs that act on dopamine receptors in the brain. They can be used as monotherapy or in combination with levodopa. This group of drugs includes rotigotine, pramipexole, apomorphine and others.
3. Monoamine oxidase B inhibitors are drugs that reduce the breakdown of dopamine in the brain by increasing its concentration. This group of drugs includes rastegilmine, selegiline, entacapone, and others.
4. Anticholinergic drugs – may help improve shaking and muscle stiffness, but are less effective than other drugs and may cause side effects such as dry mouth or constipation. This group of drugs includes trihexyphenide, biperiden, etc.

It is important to understand that each patient may require an individual approach to treatment, and drugs may be prescribed in various combinations and dosages depending on symptoms and response to therapy.

Parkinson’s drugs in the US and Europe

Levodopa

Levodopa is one of the most popular and effective Parkinson’s drugs in the US and Europe. This drug contains dopamine, the lack of which is one of the main causes of the disease.

Levodopa reduces symptoms such as trembling and muscle stiffness and improves motor function.

Anti-Parkinsonian agonists

Anti-Parkinsonian agonists are medicines that stimulate certain receptors in the brain and thus reduce the symptoms of Parkinson’s disease. These drugs are often used in combination with Levodopa to increase its effectiveness.

Some of the most commonly used anti-Parkinsonian agonists include drugs such as Ropinirole, Pramipexole and Rotigotine.

MAO-B inhibitors

MAO-B inhibitors are drugs that help keep dopamine in the brain, slowing its breakdown. These drugs are often prescribed in the early stages of Parkinson’s disease and are also used in combination with Levodopa to increase its effectiveness.

Some of the most commonly used MAO-B inhibitors in the US and Europe include the drugs Selegiline and Rasagiline.

Alternatives to tablets for the treatment of Parkinson’s disease

Parkinson’s disease is a chronic neurological disease that leads to impaired coordination of movements and reduced motor functions. Usually, this disease is treated with pills aimed at maintaining the level of dopamine in the body.

However, along with medication, there are a number of alternative methods that can help people with Parkinson’s disease.

• Exercise and Rehabilitation – Physical exercise as well as rehabilitation activities such as massage, gymnastics, yoga and dance can help restore movement and improve quality of life.
• Acupuncture – techniques that use massage and stimulation of certain points on the body can help relieve pain and improve mood.
• Proper nutrition – Proper nutrition, balanced in protein, vitamins, fats and carbohydrates, helps maintain a healthy nervous system and general physical condition.

Although these methods are not medicinal, most are considered safe and low-cost ways to improve the quality of life of people with Parkinson’s disease. However, it is important to communicate with specialists such as physicians, physical therapists, and nutritionists for specific recommendations for each method.

Related videos:

Q&A:

What is Parkinson’s disease?

Parkinson’s disease is a degenerative disease of the nervous system that results in impaired movement, persistent tremors, and other disorders.

What are the symptoms of Parkinson’s disease?

Symptoms of Parkinson’s disease include tremors, slow movements, muscle stiffness, coordination problems, memory and concentration problems, sleep and mood disturbances.

How is Parkinson’s disease treated?

Parkinson’s disease is treated with a combination of pills and exercise to help improve coordination and flexibility. Surgical treatments may also be used in severe cases.

Which tablets are used to treat Parkinson’s disease?

Levodopa, dopaminergic agonists, COMT inhibitors, MAO inhibitors, and others are commonly used to treat Parkinson’s disease. The dosage and combination of drugs depend on the severity of the symptoms and the individual characteristics of the patient.

How to use the tablets for the treatment of Parkinson’s disease?

Parkinson’s tablets should be taken as directed by your doctor. They can be taken with or without food, depending on the specific drug. It is important not to exceed the dosage and take the tablets strictly on schedule.

Can Parkinson’s disease be completely cured?

There is currently no cure for Parkinson’s disease. Treatment is aimed at improving symptoms and slowing the progression of the disease.

Self-medication for Parkinson’s disease: risk or opportunity?

The first and foremost rule in the treatment of Parkinson’s disease is not to try to choose drugs or their dosage on your own. Treatment should be prescribed only by a doctor, taking into account the individual characteristics of the patient and the stage of the disease. Only in this case can we count on a real improvement in the condition and slowing down the progression of the disease.

However, some patients search the Internet for information about the treatment of Parkinson’s disease and try various methods of self-treatment. This can have serious negative consequences, since most drugs have side effects, and improper use can lead to worsening of the condition and the development of complications.

Parkinson’s disease is a chronic disease that requires long-term and constant monitoring by a physician. Self-medication can only worsen the condition and lead to the development of complications. Patients who are already taking medication should not change the dosage on their own or interrupt the course of treatment, even if they feel better.

Of course, patients can educate themselves, learn about the disease, communicate with other patients and attend support groups. This can help them better understand their condition and reduce their anxiety levels. However, any medical advice should only be given by a qualified physician.

An integrated approach to the treatment of Parkinson’s disease

Parkinson’s disease is a chronic disease of the nervous system that leads to impaired coordination of movements and the ultimate poverty of movement. Although the treatment of Parkinson’s disease begins with medication, a comprehensive approach includes not only pharmacological therapy, but also physical and psychological support.

Medication:

Treatment for Parkinson’s disease begins with medications to help control the symptoms of the disease. The main drugs are levodopa and carbidopa, which increase dopamine levels in the brain. It is important to dose the drugs correctly and monitor their side effects.

Physical therapy:

Physical therapy can help improve coordination and muscle flexibility, as well as increase endorphins, natural pain relievers. Treatment may include exercise, massage, or yoga. The doctor may also work with the patient to develop symptom management strategies to help them cope with difficulties in daily life.

Psychological support:

For many patients, Parkinson’s disease can be physically and emotionally difficult, and can lead to reduced social activity. Psychological support can help a patient cope with emotional stress and improve quality of life by recognizing their strengths and developing strategies to maintain independence and social activity

Sample Parkinson’s treatment plan Method of treatment Goal Examples

9 0077 Physical therapy

Drug therapy	Improved symptom control	Levodopa, carbidopa
Improved coordination and flexibility of muscles	Exercise, massage, yoga
Psychological support	Coping with emotional stress and increasing social activity	Psychological counseling, strategy development

Ropinirole – description of the substance, pharmacology, use, contraindications, formula

Contents

• Structural formula

• Russian name

• English name

• Latin name

• chemical name

• Gross formula

• Pharmacological group of the substance Ropinirole

• Nosological classification

• CAS code

• pharmachologic effect

• Characteristic

• Pharmacology

• Application of Ropinirole

• Contraindications

• Application restrictions

• Use during pregnancy and lactation

• side effects of ropinirole

• Interaction

• Overdose

• Dosage and administration

• Precautionary measures

• Information sources

• Trade names with the active substance Ropinirole

Structural formula

Russian name

Ropinirole

English name

Ropinirole

Latin name

98 Ropiniroli)

Chemical name

4-(2-Dipropylaminoethyl)-1,3- Dihydodol-2-OH (in the form of hydrochloride)

gross Formula

C ₁₆ H ₂₄ N ₂ O

Pharmacological group Ropinirol

Dopaminomimetics

Antiparkinsonian drugs

Nosological classification

ICD-10 code list

CAS code

91374-21-9

Pharmacological action

Pharmacological action –

antiparkinsonian .

Characteristics

Antiparkinsonian.

Ropinirole hydrochloride is a white to yellow solid with a melting point of 243 to 250°C and a solubility in water of 133 mg/mL.

Pharmacology

Selective non-ergoline agonist of dopamine D ₂ and D ₃ receptors. A possible mechanism of action in the treatment of Parkinson’s disease is associated with a stimulating effect on postsynaptic D ₂ receptors in the basal nuclei of the brain (caudate nucleus / putamen). Ropinirole has been shown to improve motor function in animal models of Parkinson’s disease. In particular, it weakens the motor deficit caused by damage to the ascending nigrostriatal dopaminergic pathway by the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

By compensating for dopamine deficiency, ropinirole reduces the degree of physical inactivity, rigidity and tremor, which are symptoms of parkinsonism. Ropinirole enhances the effects of levodopa, including controlling the frequency of the “on/off” phenomenon and the “end of dose” effect associated with long-term therapy with levodopa drugs, and allows you to reduce the daily dose of levodopa. Ropinirole also has an effect at the level of the hypothalamus and pituitary gland, inhibiting the secretion of prolactin.

Pharmacokinetics

Absorption. In clinical studies with ropinirole immediate-release tablets, 88% of the radiolabeled substance was found in the urine, with an absolute bioavailability of 45-55% (first-pass effect through the liver). The relative bioavailability of ropinirole in the form of sustained release tablets compared to ropinirole in the form of immediate release tablets is approximately 100%. A single dose study of ropinirole sustained release tablets in healthy volunteers showed an increase in AUC of approximately 30% and C0407 max – by about 44%. In a multiple dose study in patients with Parkinson’s disease, a fat-rich meal increased AUC by approximately 20% and C _max by approximately 44%, T _max by 3 hours. C _ss is achieved within 4 days.

Distribution. Ropinirole is well distributed throughout the tissues of the body, the apparent d “> V _d is 7. 5 l / kg. Plasma protein binding is up to 40%, the blood / plasma ratio is 1: 1.

Metabolism. Ropinirole is extensively metabolized in the liver to inactive metabolites. In vitro studies”> in vitro showed that ropinirole is metabolized mainly by the CYP1A2 isoenzyme of cytochrome P450 (It is known that this isoenzyme is induced by smoking and omeprazole; inhibited by fluvoxamine, mexiletine, such “old” fluoroquinolones as ciprofloxacin, norfloxacin).

Elimination Clearance of ropinirole after oral administration – 47 l / h, T _1/2 – approximately 6 hours Excreted by the kidneys as metabolites, less than 10% – unchanged.

Pharmacokinetics in special clinical situations

Age. Clearance of ropinirole after oral administration is reduced by approximately 15% in patients aged 65 years and older compared with younger patients (dose adjustment is not required).

Pos. Clearance values ​​are similar in women and men.

Race. There were no changes in the pharmacokinetics of ropinirole depending on race.

Impaired kidney function. Population pharmacokinetic analysis showed that the pharmacokinetics of ropinirole does not change in patients with mild to moderate renal impairment. The use of ropinirole in patients with severe renal impairment has not been evaluated.

Impaired liver function. The pharmacokinetics of ropinirole have not been studied in patients with hepatic impairment. These patients may have higher plasma levels and lower clearance of ropinirole than patients with normal hepatic function.

Clinical studies

The efficacy of ropinirole extended release tablets has been demonstrated in two randomized, double-blind, multicentre clinical trials in patients with early and advanced stages of Parkinson’s disease. One study evaluated the efficacy and safety of ropinirole versus placebo as an adjunct to levodopa therapy in patients with advanced disease who were on concomitant levodopa therapy (n=393). The second study included patients with early disease who did not receive levodopa (n=161).

Use of the substance Ropinirole

According to the State Register ¹ , ropinirole in the dosage form of tablets of prolonged action is indicated for the treatment of Parkinson’s disease – monotherapy of the early stages of the disease in patients requiring dopaminergic therapy to delay the prescription of levodopa; as part of combination therapy in patients receiving levodopa preparations, in order to increase the effectiveness of levodopa, including the control of the “on-off” phenomenon and the “end of dose” effect during chronic levodopa therapy, as well as to reduce the daily dose of levodopa.

According to the PDR (2009) ² ropinirole extended release tablet formulation is indicated for the treatment of idiopathic Parkinson’s disease.

Contraindications

Hypersensitivity.

Restrictions on use

Severe cardiovascular insufficiency (see “Precautions”), a history of psychiatric disorders (may be prescribed only if the expected benefit outweighs the potential risk), impaired liver function, severe renal impairment ( Cl creatinine <30 ml / min), pregnancy, breastfeeding, age up to 18 years (safety and efficacy in children have not been determined).

Use in pregnancy and lactation

In pregnancy possible if the expected effect of therapy outweighs the potential risk to the fetus.

FDA fetal category C.

Ropinirole inhibits human prolactin secretion and has the potential to inhibit lactation. Animal studies have shown that ropinirole and/or its metabolites are excreted into the milk of lactating rats. It is not known whether ropinirole is excreted in human breast milk.

Because many drugs are excreted in a woman’s milk and because ropinirole can cause serious adverse effects on the infant, a decision should be made to either stop breastfeeding or stop taking ropinirole (depending on the mother’s need for this drug).

Adverse effects of the substance Ropinirole

Study in patients with advanced Parkinson’s disease who are on concomitant therapy with levodopa.

The most commonly observed adverse events (?5% and greater than placebo) in patients treated with ropinirole extended release tablet formulation during the 24-week study were: dyskinesia, nausea, dizziness, hallucinations, drowsiness, pain/discomfort in abdomen, orthostatic hypotension.

Approximately 6% of 202 patients treated with ropinirole sustained release tablet formulation discontinued treatment due to side effects compared with placebo patients: 5% of 191 patient. The most common side effect leading to discontinuation of ropinirole treatment was hallucinations (2%).

The table shows the side effects observed with a frequency of ?2% in patients receiving ropinirole in the dosage form of tablets of a sustained release, and exceeding the frequency of placebo.

Table

Side effects observed in double-blind, placebo-controlled trials in the treatment of patients with advanced Parkinson’s disease (with concomitant therapy with levodopa)

900 76

9 0077 2

Body systems/Adverse reactions	Ropinirole (n=202), %	Placebo (n=191), %
Ear and labyrinth disorders
Vertigo	4	2
Gastrointestinal disorders
Nausea	11	4
Constipation	4	2
Abdominal pain/discomfort	6	3
Diarrhea	3	2
Dry mouth 2	<1
General reactions
Peripheral edema	4	1
Falls (dose-dependent effect)	2	1
Disorders of the musculoskeletal system and connective tissue e			3	2
From the side of the nervous system
Dyskinesia (dose-dependent effect)	13	3 90 078
Dizziness	8	3
Drowsiness	7	4
Psychic
Hallucinations	8	2
Anxiety	1
CCC
Orthostatic hypotension	5	1
Arterial hypotension	2	0
Hypertension (dose-dependent effect)	3	2

Study in patients with early stage Parkinson’s disease (without concomitant levodopa therapy). Nausea (19%), drowsiness (11%), abdominal pain/discomfort (7%), dizziness (6%), headache (6%), constipation (5%).

It should be borne in mind that data on side effects obtained in placebo-controlled studies cannot be used to predict the occurrence of side effects in ordinary medical practice, because. patients’ condition and other factors may differ from those prevailing in clinical trials. Similarly, the frequency of occurrence of side effects (as a percentage) given in the tables may differ from that obtained by other clinical investigators, because. each drug test may be conducted with a different set of conditions. However, these figures give the physician an idea of ​​the relative contribution of the substance itself and other factors (not related to drugs) to the development of side effects when using drugs in the population.

Interaction

in studies in vitro “> in vitro shows that Ropinirol is metabolized mainly with the participation of the CYP1A2 of the CYTOCHROM P450. Accordingly, inhibiting (for example, drugs such as ciprofloxine, fluvoxamine) or induction) CYP1A2 isoenzyme can change the clearance of ropinirole.In this regard, in the case of termination or initiation of treatment with strong inducers or inhibitors of CYP1A2 during therapy with ropinirole, dose adjustment may be necessary.0003

Ciprofloxacin. Co-administration of ciprofloxacin, a CYP1A2 inhibitor (500 mg twice daily) and ropinirole immediate-release tablets (2 mg 3 times daily) resulted in an increase in max”>C _max and AUC of ropinirole by approximately 60% and 84%, respectively (n=12 patients)

Cigarette smoking appears to increase clearance of ropinirole as smoking is known to stimulate this isoenzyme

Levodopa Co-administration of carbidopa + levodopa (10/100 mg twice per day) with ropinirole (2 mg 3 times a day) did not affect the equilibrium pharmacokinetics of ropinirole (n = 28 patients). Oral administration of ropinirole (2 mg 3 times a day) led to an increase in the equilibrium value0407 max levodopa by 20%, but did not affect AUC (n=23 patients).

Digoxin. Co-administration of ropinirole (2 mg 3 times daily) with digoxin (0.125 mg–0.25 mg 1 time daily) did not affect the steady-state pharmacokinetics of digoxin (n=10 patients).

Theophylline. A pharmacokinetic drug interaction study in 12 patients with Parkinson’s disease showed that the use of theophylline, which is a substrate of the CYP1A2 isoenzyme (300 mg twice a day) and ropinirole (2 mg 3 times a day), did not change the pharmacokinetics of ropinirole at equilibrium. Ropinirole (2 mg 3 times a day) did not affect the pharmacokinetics of theophylline (5 mg/kg IV).

Estrogens. A population pharmacokinetic analysis found that high dose estrogens (usually used in hormone replacement therapy – HRT) reduce the oral clearance of ropinirole by approximately 35% (n=16 patients). In patients who received HRT before the start of treatment with ropinirole, no dose adjustment is required, but the dose of ropinirole should be adjusted if HRT is started or stopped during treatment with ropinirole.

Dopamine antagonists. Since ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may reduce the effectiveness of ropinirole (simultaneous administration should be avoided).

Population analysis showed that commonly prescribed drugs such as selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines and anticholinergics do not affect the oral clearance of ropinirole.

Overdose

Symptoms: when taken more than 24 mg/day – mainly due to dopaminergic activity (nausea, dizziness), as well as visual hallucinations, hyperhidrosis, claustrophobia, chorea, palpitations, asthenia, nightmares, vomiting, drowsiness . In addition, when taking less than 24 mg / day (or if the dose is unknown), vomiting, coughing, fatigue, fainting, incl. vasovagal, dyskinesia, agitation, chest pain, orthostatic hypotension, drowsiness, state of confusion.

Treatment: administration of dopamine antagonists such as neuroleptics or metoclopramide, maintenance therapy.

Dosage and administration

Inside . The dosage regimen is selected individually, depending on the effectiveness and tolerability of the drug. A dose reduction is recommended if the patient experiences drowsiness at any stage of dose selection. With the development of other adverse reactions, it is necessary to reduce the dose of the drug, followed by a gradual increase. It should be borne in mind the need to titrate the dose when skipping a dose (one or more). Cancellation should be carried out gradually, reducing the daily dose for at least 1 week.

In elderly patients, as well as in patients with impaired renal function, dose titration is carried out as usual, in patients with impaired liver function – with caution.

Precautions

Drowsiness and sudden sleep attacks. Patients should be warned about the possibility of drowsiness or sudden sleep episodes during therapy with ropinirole, which may lead to injury. In the event of such reactions, it is necessary to provide for the possibility of discontinuing therapy with ropinirole.

Syncope . Syncope, sometimes associated with bradycardia, has been reported during treatment with ropinirole. Thus, in a placebo-controlled study, syncope was recorded in 2 of 202 (1%) patients with an advanced stage of the disease and in none of the patients in the placebo group.

Since patients with severe cardiovascular insufficiency were not included in clinical studies of ropinirole extended release, use with caution in this category of patients (see “Restrictions for use”).

Arterial hypotension. Dopamine agonists interfere with the systemic regulation of blood pressure and may therefore lead to postural hypotension. In patients with Parkinson’s disease taking ropinirole, blood pressure monitoring is recommended. Arterial hypotension, incl. orthostatic, can develop both at the time of dose titration and during maintenance therapy.

Increased blood pressure and changes in heart rate. In a placebo-controlled trial of ropinirole in patients with advanced Parkinson’s disease, there was no significant change in mean blood pressure and heart rate in patients treated with ropinirole compared with placebo. However, a marked increase in SBP (≥40 mmHg) was recorded in the reclining position in 8% of patients in the ropinirole group compared with 5% in the placebo group, in the standing position – in 9and 6% respectively. An increase in heart rate (≥15 bpm) in the reclining position was observed in 23% of patients in the ropinirole group compared with 18% of patients in the placebo group, a decrease in heart rate (≥15 bpm) in 19 and 17% of cases respectively. In the standing position, a marked increase in heart rate (≥30 bpm) was recorded with ropinirole in 2% of cases compared with <1% placebo and a moderate decrease in heart rate (≥15 bpm) - 24 and 19% respectively.

An increase in blood pressure and a change in heart rate were observed both at the time of dose titration and during maintenance therapy.

The possibility of increased blood pressure and changes in heart rate should be considered when treating patients with cardiovascular disease with ropinirole (see “Restrictions on use”).

Hallucinations. The incidence of hallucinations is increased in patients over 65 years of age. Co-administration of entacapone and levodopa with ropinirole may also increase the risk of this adverse effect. In a placebo-controlled clinical trial, 43 patients treated with both entacapone and levodopa did not experience hallucinations; patients treated with sustained release ropinirole concomitantly with levodopa had hallucinations.patients out of 155 (6%) who received entacapone, ropinirole and levodopa at the same time – in 7 patients out of 47 (15%).

Dyskinesia. Extended release ropinirole potentiates the dopaminergic side effect of levodopa and may induce and/or exacerbate pre-existing dyskinesia in levodopa-treated patients with Parkinson’s disease. Reducing the dose of dopaminergic drugs can reduce this adverse effect.